Doxorubicin-induced mitochondrial dysfunction is secondary to nuclear p53 activation in H9c2 cardiomyoblasts

Area of Science:

• Cardiology
• Molecular Biology
• Pharmacology

Background:

• Doxorubicin (DOX) is a vital chemotherapeutic agent.
• DOX can induce cardiotoxicity, leading to myocyte apoptosis.
• The precise mechanism of DOX-induced cardiotoxicity requires further elucidation.

Purpose of the Study:

• To investigate the role of nuclear effects in Doxorubicin-induced myocyte apoptosis.
• To determine if mitochondrial dysfunction is a primary or secondary event in DOX cardiotoxicity.

Main Methods:

• H9c2 myoblasts were treated with varying concentrations of Doxorubicin (0, 0.5, 1 muM).
• Nuclear and mitochondrial alterations were assessed.
• Key proteins (p53, Bax, caspases) and mitochondrial potential were measured.
• The effect of a p53 inhibitor (pifithrin-alpha) was evaluated.

Main Results:

• Doxorubicin accumulated in the nucleus, followed by p53 activation.
• Mitochondrial membrane potential decreased, and apoptotic markers (caspase activation, chromatin condensation) increased.
• Bax and p53 translocated to mitochondria.
• Pifithrin-alpha mitigated DOX-induced mitochondrial depolarization, caspase activation, and cell death.

Conclusions:

• Doxorubicin-induced mitochondrial dysfunction in H9c2 myoblasts is mediated by nuclear p53 activation.
• The cardiotoxic effects of Doxorubicin are secondary to its nuclear actions, not direct mitochondrial damage.